Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of DA-90 vs DAC Induction and FLAG-IDA vs CLAG-M Salvage in AML
NCT03257241Phase 3Unknown
- Sponsor
- Polish Adult Leukemia Group
- Start
- Jul 2017
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of cladribine in acute myeloid leukemia (AML) (4 arms), sponsored by Polish Adult Leukemia Group. Primary endpoints: Complete Remission Rate after Induction I and Complete Remission Rate after Induction II. Status: unknown.
02
Drugs
cladribine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03257241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03257241.